CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CERO CERo Therapeutics Holdings, Inc.

Trading 11-14 11:23:06 EST

0.1830

-0.0289

-13.64%

High0.2077	Low0.1801	Vol7.81M
Open0.2077	D1 Closing0.2119	Amplitude13.03%
Mkt Cap27.51M	Tradable Cap12.22M	Total Shares150.31M
T/O1.50M	T/O Rate11.70%	Tradable Shares66.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":0.183,"timestamp":1731601364887,"preClose":0.2119,"halted":0,"volume":7810256,"delay":0,"floatShares":66749779,"shares":150307957,"eps":-0.304165,"marketStatus":"Trading","change":-0.0289,"latestTime":"11-14 11:23:06 EST","open":0.2077,"high":0.2077,"low":0.1801,"amount":1496380.3806803199,"amplitude":0.13025,"askPrice":0.185,"askSize":500,"bidPrice":0.1805,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.304165,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1731618000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.2119,"preHourTrading":{"tag":"盘前","latestPrice":0.1976,"preClose":0.2119,"latestTime":"09:29 EST","volume":1025302,"amount":193942.41472676,"timestamp":1731594592121},"postHourTrading":{"tag":"盘后","latestPrice":0.1949,"preClose":0.2119,"latestTime":"19:59 EST","volume":1634771,"amount":330351.708698,"timestamp":1731545975963},"volumeRatio":0.058856},"requestUrl":"/m/hq/s/CERO/tweets","defaultTab":"tweets","newsList":[{"id":"2482757527","title":"CERo Therapeutics’ (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2482757527","media":"TIPRANKS","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482757527?lang=en_us&edition=fundamental","pubTime":"2024-11-12 17:41","pubTimestamp":1731404493,"startTime":"0","endTime":"0","summary":"CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound CER-1236.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/cero-therapeutics-cero-stock-sees-significant-climb-after-revealing-ovarian-cancer-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/cero-therapeutics-cero-stock-sees-significant-climb-after-revealing-ovarian-cancer-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2482763981","title":"Sector Update: Health Care Stocks Softer Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2482763981","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482763981?lang=en_us&edition=fundamental","pubTime":"2024-11-12 04:57","pubTimestamp":1731358626,"startTime":"0","endTime":"0","summary":"Health care stocks fell late Monday afternoon with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund  shedding 0.7%.The iShares Biotechnology ETF  declined 0.6%.In corporate news, Evotec  shares surged 18% after Bloomberg reported the company is the subject of a potential takeover bid by Triton Partners.RAPT Therapeutics  shares plunged 39% after the company said Monday it's ending its zelnecirnon program after the US Food and Drug Administration put a hold on two trials assessing the drug as a potential treatment for asthma and atopic dermatitis.CERo Therapeutics  shares soared 165%. The company said Monday that it presented preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.AbbVie  shares tumbled 12%. The company said its two phase 2 trials assessing emraclidine in adult patients with schizophrenia and acute exacerbation of psycho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0795875086.SGD","BK4566","LU1003077747.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0820561909.HKD","LU0708994859.HKD","LU0256863811.USD","XLV","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0795875169.SGD","IE00BDGV0183.EUR","BK4559","BK4534","LU0256863902.USD","BK4550","LU0661504455.SGD","BK7132","LU0203345920.USD","CERO","IE00BVYPNV92.GBP","LU0211327993.USD","LU0861579265.USD","LU0965509010.AUD","LU0203347892.USD","LU1023059063.AUD","LU0965508806.USD","IE00BSNM7G36.USD","LU0943347566.SGD","IBB","ABBV","LU0114720955.EUR","BK4581","LU0029864427.USD","LU0128525929.USD","EVO.AU","LU0198837287.USD","LU0211328371.USD","LU0310799852.SGD","LU0456855351.SGD","LU0553294199.USD","LU0912757837.SGD","EVO","IE00B3PB1722.GBP","LU0545039389.USD","LU0170899867.USD","LU0738911758.USD","RAPT","BK4121"],"gpt_icon":0},{"id":"2482675434","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2482675434","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482675434?lang=en_us&edition=fundamental","pubTime":"2024-11-12 03:08","pubTimestamp":1731352135,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said on Monday that it presented preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.Shares surged 140% as intraday trading volume soared to more than 1.16 billion from a daily average of about 8.8 million.RadNet  shares soared as Q3 adjusted earnings and revenue reported late Sunday rose more than forecast.Shares advanced 20% as intraday trading volume climbed to over 1.8 million from a daily average of about 523,000.Jefferies was one of several brokerage firms to adjust its price target for Bristol-Myers Squibb . It raised the price target to $63 from $58 while maintaining the hold rating.Shares of Bristol-Myers jumped 11%, with intraday trading volume at over 18.3 million compared with a daily average of about 10.6 million.Price: 0.17, Change: +0.10, Percent Change: +140.00","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU1585245621.USD","LU0225771236.USD","LU1670710661.SGD","CERO","LU1670710588.SGD","LU1074936037.SGD","LU1032466523.USD","LU1571399168.USD","BK4196","BK4139","IE0002141913.USD","BK4585","LU0306806265.USD","LU0985481810.HKD","LU1670711123.USD","LU1670711040.USD","BMY","LU0868494617.USD","BK4532","LU1989771016.USD","LU0306807586.USD","BK4559","BK4581","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU2360032135.SGD","LU0114720955.EUR","LU0321505868.SGD","BK4534","BK4007","LU0882574055.USD","LU0321505439.SGD","IE00BSNM7G36.USD","LU1261432733.SGD","LU0456855351.SGD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU0061475181.USD","LU1718418525.SGD","LU2065731478.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2242652126.USD","LU2125154778.USD","LU2133065610.SGD","RDNT","LU1093756168.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2482738020","title":"Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2482738020","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482738020?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:49","pubTimestamp":1731336596,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/24/11/41879774/dow-jumps-over-400-points-monday-com-shares-fall-after-q3-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU1720051108.HKD","PSQ","LU1720051017.SGD","PCOM","LU2357305700.SGD","BK4122","SQQQ","BK4539","LU1548497426.USD","HOVR","QLD","MNDY","NXL","NQmain","BK4590","LU2065171402.SGD","RAPT","EFSH","BK4585","LU2065169927.USD",".IXIC","BK4187","BK4588","LU2065170008.USD","BK4139","MNQmain","BK4206","BK4097","TQQQ","BK4082","CERO","FOXO","QID","BK4023"],"gpt_icon":1},{"id":"2482817227","title":"Cero Therapeutics presents preclinical data on CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2482817227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482817227?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:26","pubTimestamp":1731331563,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-presents-preclinical-data-on-cer-1236?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-presents-preclinical-data-on-cer-1236?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","CERO"],"gpt_icon":0},{"id":"2480869885","title":"BRIEF-Cero Therapeutics Holdings fails to regain compliance with Nasdaq MVLS requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480869885","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480869885?lang=en_us&edition=fundamental","pubTime":"2024-11-02 06:12","pubTimestamp":1730499144,"startTime":"0","endTime":"0","summary":"Nov 1 (Reuters) - CERo Therapeutics Holdings Inc :   * CERO THERAPEUTICS HOLDINGS INC - FAILS TO REGAIN COMPLIANCE WITH NASDAQ MVLS REQUIREMENTSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NQmain","BK4588","IE00B64PRP62.GBP","SQQQ","MNQmain","QID","IE00BKPKM429.USD","PSQ","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","NDAQ","CERO","QLD","LENZ","BK4112","LU2210150020.SGD","TQQQ","LU2095319765.USD",".IXIC"],"gpt_icon":0},{"id":"2480868606","title":"Cero Therapeutics Holdings Inc - Fails to Regain Compliance With Nasdaq Mvls Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480868606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480868606?lang=en_us&edition=fundamental","pubTime":"2024-11-02 05:05","pubTimestamp":1730495154,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nFWN3M81MF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2477811369","title":"Cero Therapeutics files to sell 713.56M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2477811369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477811369?lang=en_us&edition=fundamental","pubTime":"2024-10-22 04:45","pubTimestamp":1729543509,"startTime":"0","endTime":"0","summary":"16:44 EDT Cero Therapeutics (CERO) files to sell 713.56M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-files-to-sell-713-56m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-files-to-sell-713-56m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","CERO"],"gpt_icon":0},{"id":"2477685798","title":"BRIEF-Cero Therapeutics, Inc. Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2477685798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477685798?lang=en_us&edition=fundamental","pubTime":"2024-10-21 21:19","pubTimestamp":1729516742,"startTime":"0","endTime":"0","summary":"Oct 21  - CERo Therapeutics Holdings Inc :   * CERO THERAPEUTICS, INC. PROVIDES CORPORATE UPDATE   * CERO THERAPEUTICS HOLDINGS: TO ADJUST OUR PREVIOUS GUIDANCE ABOUT POTENTIAL ENTRY INTO CLINIC FROM 2024 TO EARLY 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","CERO"],"gpt_icon":0},{"id":"2477857099","title":"Cero Therapeutics Holdings: to Adjust Our Previous Guidance About Potential Entry Into Clinic From 2024 to Early 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2477857099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477857099?lang=en_us&edition=fundamental","pubTime":"2024-10-21 21:00","pubTimestamp":1729515601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA4ZCMVB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2477857087","title":"Cero Therapeutics, Inc. Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2477857087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477857087?lang=en_us&edition=fundamental","pubTime":"2024-10-21 21:00","pubTimestamp":1729515601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA4ZCMVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2472240395","title":"CERo Therapeutics Names Andrew Kucharchuk CFO, Kristen Pierce Chief Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2472240395","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472240395?lang=en_us&edition=fundamental","pubTime":"2024-10-02 22:42","pubTimestamp":1727880123,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said Wednesday that Andrew Kucharchuk has been named chief financial officer.Kucharchuk previously served as CFO of both Nukkelous and Chain Bridge I, the company said.CERo also named Kristen Pierce chief development officer. Pierce was previously vice president of translational medicine at Pionyr Therapeutics, CERo said.Price: 0.09, Change: -0.01, Percent Change: -9.36","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","5FL.SI","CERO"],"gpt_icon":0},{"id":"2472579649","title":"CERo Therapeutics gets new finance head","url":"https://stock-news.laohu8.com/highlight/detail?id=2472579649","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472579649?lang=en_us&edition=fundamental","pubTime":"2024-10-02 22:25","pubTimestamp":1727879135,"startTime":"0","endTime":"0","summary":"Innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics—CERo Therapeutics  appointed new heads to support recently named interim CEO,Chris Ehrlich.Andrew Albert “Al” Kucharchuk has been named CFO andKristen Pierce, Ph.D., has been appointed Chief Development Officer.Mr. Kucharchukjoins CERo  from Nukkelous and Chain Bridge I, both Nasdaq-traded companies where he served as CFO.Prior to joining CERo, Kristen was VP, Translational Medicine at Pionyr Therapeutics.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4155530-cero-therapeutics-gets-new-finance-head","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2472252386","title":"Cero Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2472252386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472252386?lang=en_us&edition=fundamental","pubTime":"2024-10-02 21:15","pubTimestamp":1727874900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nTUA12XRMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2472523555","title":"CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2472523555","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472523555?lang=en_us&edition=fundamental","pubTime":"2024-10-02 21:15","pubTimestamp":1727874900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024  -- CERo Therapeutics Holdings, Inc.  , an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company’s management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer.About CERo Therapeutics, Inc.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T6sFa8GpShiuFtG._zLWDw--~B/aD00Mjk7dz04ODc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d6252fbe33e9cbb1b271a88446c93bd3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T6sFa8GpShiuFtG._zLWDw--~B/aD00Mjk7dz04ODc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d6252fbe33e9cbb1b271a88446c93bd3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-inc-names-al-131500506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","BK4139","CERO","LENZ"],"gpt_icon":0},{"id":"2470269957","title":"CERo Therapeutics says CEO Atwood, CFO Carter to step down","url":"https://stock-news.laohu8.com/highlight/detail?id=2470269957","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470269957?lang=en_us&edition=fundamental","pubTime":"2024-09-25 22:58","pubTimestamp":1727276317,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said its CEO, Brian Atwood, has decided to step down from the role, and vice chair Chris Ehrlich will become the interim chief. Ehrlich will also take the role of the chair. CFO, Charles Carter, and its chief technology officer, Daniel Corey have also decided to step down.  The firm also said its existing investors have committed a financing of $1.25 million. The company plans to work with the U.S. Food and Drug Administration to resolve the remaining IND issue for CER-1236, which is on clinical hold with the funds.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4153166-cero-therapeutics-says-ceo-atwood-cfo-carter-to-step-down","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2470926999","title":"CERo Therapeutics Names Interim CEO, Secures Financing; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2470926999","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470926999?lang=en_us&edition=fundamental","pubTime":"2024-09-25 22:58","pubTimestamp":1727276299,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said Wednesday that Chief Executive and President Brian Atwood, Chief Financial Officer Charles Carter and Chief Technology Officer Daniel Corey have decided to step down from their respective positions.The company named Vice Chairman Chris Ehrlich as chairman and interim CEO and said Atwood will become a consultant to CERo while remaining on the board.CERo also said its existing investors have committed a $1.25 million financing, allowing it to work with the US Food and Drug Administration to resolve the remaining investigational new drug application issue for its lead product candidate CER-1236, which is on clinical hold.The company's shares were up about 17% in recent trading.Price: 0.11, Change: +0.02, Percent Change: +17.29","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","CERO"],"gpt_icon":0},{"id":"2470226880","title":"Dow Falls Over 50 Points; Cintas Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2470226880","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470226880?lang=en_us&edition=fundamental","pubTime":"2024-09-25 21:53","pubTimestamp":1727272430,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/41025717/dow-falls-over-50-points-cintas-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTAS","VTNR","ATCH","OCTO","PCOM","CERO","SFIX","CMCT"],"gpt_icon":0},{"id":"2470524432","title":"Cero Therapeutics Holdings Inc - Requests Type a Meeting With FDA for Cer-1236 Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2470524432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470524432?lang=en_us&edition=fundamental","pubTime":"2024-09-25 21:17","pubTimestamp":1727270220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240925:nTUA3N5J3H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2470446252","title":"Cero Therapeutics Holdings Inc - Secures $1.25 Million Financing From Existing Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2470446252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470446252?lang=en_us&edition=fundamental","pubTime":"2024-09-25 21:17","pubTimestamp":1727270220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240925:nTUA3N5J3H:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cero.bio","stockEarnings":[{"period":"1week","weight":1.9431},{"period":"1month","weight":1.1469},{"period":"3month","weight":0.4318},{"period":"6month","weight":-0.8074},{"period":"1year","weight":-0.9805},{"period":"ytd","weight":-0.9807}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.022},{"period":"3month","weight":0.0798},{"period":"6month","weight":0.1279},{"period":"1year","weight":0.3308},{"period":"ytd","weight":0.2564}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.008744},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.242544},{"month":3,"riseRate":1,"avgChangeRate":0.019563},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.170363},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.11752},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.223411},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.161759},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.060279},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.086633},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.023845},{"month":11,"riseRate":0.666667,"avgChangeRate":0.492193},{"month":12,"riseRate":0.666667,"avgChangeRate":0.004302}],"exchange":"NASDAQ","name":"CERo Therapeutics Holdings, Inc.","nameEN":"CERo Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CERo Therapeutics Holdings, Inc.,CERO,CERo Therapeutics Holdings, Inc.股票,CERo Therapeutics Holdings, Inc.股票老虎,CERo Therapeutics Holdings, Inc.股票老虎国际,CERo Therapeutics Holdings, Inc.行情,CERo Therapeutics Holdings, Inc.股票行情,CERo Therapeutics Holdings, Inc.股价,CERo Therapeutics Holdings, Inc.股市,CERo Therapeutics Holdings, Inc.股票价格,CERo Therapeutics Holdings, Inc.股票交易,CERo Therapeutics Holdings, Inc.股票购买,CERo Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}